News

  • 10 December 2009

    Endosense, a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias, has announced the appointment of health-care industry veterans Jan H. Egberts, M.D. and Michael J. Dormer, to new chairman of the board and board director, respectively. Representing several decades of senior management experience at industry-leading medical device and pharmaceutical companies, the two join Endosense as it pursues the European commercialization and U.S. Premarket Approval (PMA) clinical study of the company’s proprietary force-sensing ablation catheter, the TactiCath®.

  • 2 December 2009

    NovaShunt today announced the appointment of Dr. Pedro Eerdmans as Chief Medical Officer and Dan Rose as Vice President of Commercial Operations and member of the Company’s Board of Directors.

  • 5 October 2009

    Santhera Pharmaceuticals (SIX: SANN), a Swiss specialty pharmaceutical company focused on orphan neuromuscular diseases, announced today the final closing of the acquisition of Oy Juvantia Pharma Ltd of Turku, Finland. Santhera issued 105,973 previously reserved shares from its authorized share capital to Juvantia investors, as announced when exercising its option to acquire Juvantia on August 17, 2009. The closing of the transaction triggers a final upfront payment of USD 4 million from Biovail Laboratories International SRL, a sububsidiary of Biovail Corporation, Santhera's licensing partner for the further development and marketing of JP-1730/fipamezole to treat Dyskinesia in Parkinson's Disease in the United States and Canada.

  • 1 September 2009

    Endosense, a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias, has announced that it has received USD 36 million in Series B financing. Edmond de Rothschild Investment Partners (EdRIP) led the round, with additional participation from Neomed, Gimv, VI Partners (VI), Sectoral Asset Management, Ysios Capital Partners and Initiative Capital Romandie. The financing will primarily be used to fund the European commercialization and U.S. Premarket Approval (PMA) clinical study of the company’s proprietary force-sensing ablation catheter, the TactiCath®.

  • 15 May 2009

    Endosense has announced the release of acute clinical results from the TOCCATA (TOuCh+ for CATheter Ablation) European clinical trial at Heart Rhythm 2009, the Heart Rhythm Society’s 30th Annual Scientific Sessions in Boston, May 13 - 16. The highly anticipated results of the 76-patient, multi-center study confirm the feasibility, safety and value of Endosense’s TactiCath force-sensing ablation catheter during catheter ablation.